Sutro Biopharma (STRO) Competitors $0.78 +0.04 (+5.90%) Closing price 04:00 PM EasternExtended Trading$0.77 -0.01 (-1.47%) As of 07:56 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrendsBuy This Stock STRO vs. IMMP, ACB, SGMT, TVGN, SLRN, CGC, NBTX, BTMD, MNPR, and SLSShould you be buying Sutro Biopharma stock or one of its competitors? The main competitors of Sutro Biopharma include Prima BioMed (IMMP), Aurora Cannabis (ACB), Sagimet Biosciences (SGMT), Semper Paratus Acquisition (TVGN), Acelyrin (SLRN), Canopy Growth (CGC), Nanobiotix (NBTX), biote (BTMD), Monopar Therapeutics (MNPR), and SELLAS Life Sciences Group (SLS). These companies are all part of the "pharmaceutical products" industry. Sutro Biopharma vs. Its Competitors Prima BioMed Aurora Cannabis Sagimet Biosciences Semper Paratus Acquisition Acelyrin Canopy Growth Nanobiotix biote Monopar Therapeutics SELLAS Life Sciences Group Sutro Biopharma (NASDAQ:STRO) and Prima BioMed (NASDAQ:IMMP) are both small-cap medical companies, but which is the better business? We will compare the two businesses based on the strength of their earnings, institutional ownership, dividends, risk, profitability, analyst recommendations, valuation and media sentiment. Do analysts prefer STRO or IMMP? Sutro Biopharma currently has a consensus price target of $6.11, indicating a potential upside of 679.39%. Prima BioMed has a consensus price target of $7.00, indicating a potential upside of 311.76%. Given Sutro Biopharma's higher possible upside, equities analysts clearly believe Sutro Biopharma is more favorable than Prima BioMed.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Sutro Biopharma 1 Sell rating(s) 4 Hold rating(s) 3 Buy rating(s) 0 Strong Buy rating(s) 2.25Prima BioMed 0 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 3.00 Do insiders and institutionals believe in STRO or IMMP? 97.0% of Sutro Biopharma shares are owned by institutional investors. Comparatively, 2.3% of Prima BioMed shares are owned by institutional investors. 5.9% of Sutro Biopharma shares are owned by insiders. Comparatively, 3.1% of Prima BioMed shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth. Which has stronger valuation & earnings, STRO or IMMP? Prima BioMed has lower revenue, but higher earnings than Sutro Biopharma. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioSutro Biopharma$62.04M1.07-$227.46M-$2.98-0.26Prima BioMed$5.14M48.30-$28.01MN/AN/A Which has more volatility and risk, STRO or IMMP? Sutro Biopharma has a beta of 1.64, indicating that its share price is 64% more volatile than the S&P 500. Comparatively, Prima BioMed has a beta of 1.71, indicating that its share price is 71% more volatile than the S&P 500. Does the media favor STRO or IMMP? In the previous week, Sutro Biopharma's average media sentiment score of 0.00 equaled Prima BioMed'saverage media sentiment score. Company Overall Sentiment Sutro Biopharma Neutral Prima BioMed Neutral Is STRO or IMMP more profitable? Prima BioMed has a net margin of 0.00% compared to Sutro Biopharma's net margin of -373.66%. Prima BioMed's return on equity of 0.00% beat Sutro Biopharma's return on equity.Company Net Margins Return on Equity Return on Assets Sutro Biopharma-373.66% -347.60% -59.46% Prima BioMed N/A N/A N/A SummaryPrima BioMed beats Sutro Biopharma on 7 of the 12 factors compared between the two stocks. Get Sutro Biopharma News Delivered to You Automatically Sign up to receive the latest news and ratings for STRO and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding STRO and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart STRO vs. The Competition Export to ExcelMetricSutro BiopharmaMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$62.57M$2.88B$5.47B$8.95BDividend YieldN/A2.46%5.25%4.06%P/E Ratio-0.267.5719.7120.50Price / Sales1.07286.98435.75120.29Price / CashN/A41.1936.8257.86Price / Book1.457.487.985.56Net Income-$227.46M-$55.04M$3.16B$248.40M7 Day Performance15.37%5.44%3.69%6.04%1 Month Performance-7.49%2.38%2.91%7.69%1 Year Performance-74.19%5.53%34.30%20.97% Sutro Biopharma Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)STROSutro Biopharma3.1919 of 5 stars$0.78+5.9%$6.11+679.4%-74.6%$62.57M$62.04M-0.26240IMMPPrima BioMed0.9837 of 5 stars$1.64flat$7.00+326.8%-13.4%$239.50MN/A0.002,021Positive NewsACBAurora Cannabis0.0982 of 5 stars$4.24+2.2%N/A-8.1%$238.35M$343.29M38.551,130SGMTSagimet Biosciences2.4052 of 5 stars$7.62-3.2%$26.60+249.1%+193.2%$233.71M$2M-4.338TVGNSemper Paratus Acquisition3.9649 of 5 stars$1.25+0.8%$10.00+700.0%+71.4%$229.86MN/A0.003Positive NewsSLRNAcelyrinN/A$2.27flat$9.60+322.9%N/A$229.17MN/A-0.92135CGCCanopy Growth2.8147 of 5 stars$1.22flat$2.00+63.9%-81.1%$224.32M$225.65M-0.303,150News CoverageNBTXNanobiotix1.6904 of 5 stars$4.73+4.4%$8.00+69.1%-13.1%$222.93M$39.18M0.00100News CoverageGap UpBTMDbiote3.251 of 5 stars$4.02-4.3%$8.00+99.0%-46.0%$219.93M$197.19M6.59194News CoveragePositive NewsMNPRMonopar Therapeutics2.9043 of 5 stars$35.78+6.5%$56.50+57.9%+933.2%$218.97MN/A-10.2810News CoverageAnalyst ForecastSLSSELLAS Life Sciences Group0.1213 of 5 stars$2.19+12.3%N/A+79.3%$218.52M$1M-5.7610News CoverageHigh Trading Volume Related Companies and Tools Related Companies Prima BioMed Alternatives Aurora Cannabis Alternatives Sagimet Biosciences Alternatives Semper Paratus Acquisition Alternatives Acelyrin Alternatives Canopy Growth Alternatives Nanobiotix Alternatives biote Alternatives Monopar Therapeutics Alternatives SELLAS Life Sciences Group Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:STRO) was last updated on 7/8/2025 by MarketBeat.com Staff From Our PartnersEveryone’s watching Nvidia right now. Here’s why I’m excited.So, unless you’ve been living under a rock, you probably saw the news… Nvidia just signed a $7 BILLION deal...Timothy Sykes | SponsoredThis Signal Only Flashes Once Every 4 Years – And It Just TriggeredThis same signal has appeared twice before in the past 8 years — both times, it kicked off major moves in cryp...Crypto Swap Profits | Sponsored$100 Trillion “AI Metal” Found in American Ghost TownJeff Brown recently traveled to a ghost town in the middle of an American desert… To investigate what could...Brownstone Research | Sponsored$3,200 from your phone?No charts. No crypto. No stock picking. With just a regular brokerage app and Jeff Clark’s “Crossfire” meth...TradeSmith | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredTrump’s treachery Trump’s Final Reset Inside the shocking plot to re-engineer America’s financial system…and why you need to ...Porter & Company | SponsoredTrump set to Boost Social Security Checks by 400%?If you're collecting or planning to collect social security... You should see this presentation about Presi...InvestorPlace | SponsoredThe day and month stocks are most likely to crash nextGood News for Stocks 50-year Wall Street veteran, Marc Chaikin is stepping forward to share why history giv...Chaikin Analytics | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Sutro Biopharma, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Sutro Biopharma With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.